Have a feature idea you'd love to see implemented?
Let us know!
EOLS Evolus Inc
Price (delayed)
$13.04
Market cap
$825.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.9
Enterprise value
$870.55M
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only
Highlights
EOLS's gross profit is up by 35% year-on-year and by 5% since the previous quarter
Evolus's revenue has increased by 34% YoY and by 4.7% QoQ
Evolus's equity has surged by 130% YoY but it has shrunk by 70% QoQ
The quick ratio has soared by 50% year-on-year but it has declined by 16% since the previous quarter
The debt rose by 28% year-on-year and by 2.5% since the previous quarter
Key stats
What are the main financial stats of EOLS
Market
Valuations
Earnings
Shares outstanding
63.32M
Market cap
$825.71M
Enterprise value
$870.55M
Price to earnings (P/E)
N/A
Price to book (P/B)
139.69
Price to sales (P/S)
3.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.51
Revenue
$248.33M
EBIT
-$36.89M
EBITDA
-$30.97M
Free cash flow
-$25.82M
Per share
Balance sheet
Liquidity
EPS
-$0.9
Free cash flow per share
-$0.41
Book value per share
$0.09
Revenue per share
$3.93
TBVPS
$2.56
Total assets
$229.61M
Total liabilities
$223.72M
Debt
$129.88M
Equity
$5.89M
Working capital
$89.55M
Debt to equity
22.05
Current ratio
2.47
Quick ratio
2.13
Net debt/EBITDA
-1.45
Margins
Efficiency
Dividend
EBITDA margin
-12.5%
Gross margin
69.9%
Net margin
-22.3%
Operating margin
-16.4%
Return on assets
-25.3%
Return on equity
-966.3%
Return on invested capital
-26%
Return on capital employed
-21.9%
Return on sales
-14.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EOLS stock price
How has the Evolus stock price performed over time
Intraday
3.25%
1 week
9.76%
1 month
-19.7%
1 year
38.43%
YTD
23.84%
QTD
-19.51%
Financial performance
How have Evolus's revenue and profit performed over time
Revenue
$248.33M
Gross profit
$173.69M
Operating income
-$40.73M
Net income
-$55.46M
Gross margin
69.9%
Net margin
-22.3%
The company's operating margin rose by 41% YoY
The net margin rose by 35% year-on-year
EOLS's gross profit is up by 35% year-on-year and by 5% since the previous quarter
Evolus's revenue has increased by 34% YoY and by 4.7% QoQ
Growth
What is Evolus's growth rate over time
Valuation
What is Evolus stock price valuation
P/E
N/A
P/B
139.69
P/S
3.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.51
The company's EPS rose by 20% YoY
Evolus's equity has surged by 130% YoY but it has shrunk by 70% QoQ
Evolus's revenue has increased by 34% YoY and by 4.7% QoQ
The P/S is 21% less than the 5-year quarterly average of 4.2 and 2.4% less than the last 4 quarters average of 3.4
Efficiency
How efficient is Evolus business performance
The ROIC has grown by 48% YoY and by 2.3% from the previous quarter
The company's return on sales rose by 45% YoY
Evolus's ROA has increased by 32% YoY and by 3.1% from the previous quarter
Dividends
What is EOLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EOLS.
Financial health
How did Evolus financials performed over time
The total assets is 2.6% more than the total liabilities
The quick ratio has soared by 50% year-on-year but it has declined by 16% since the previous quarter
The total assets has increased by 37% YoY
Evolus's equity has surged by 130% YoY but it has shrunk by 70% QoQ
The debt rose by 28% year-on-year and by 2.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.